Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease

2018108 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov, Identifier: NCT02077374.

Good health and well-being

Published in: Alimentary Pharmacology & Therapeutics

Volume 49, Issue 1, pp. 64-73

Field-Weighted Citation Impact: 8.43